ASSEMBLY BIOSCIENCES DOSES FIRST TWO PARTICIPANTS IN PHASE 2 STUDY OF ORAL NTCP INHIBITOR ABI-6250 FOR CHRONIC HEPATITIS DELTA VIRUS

Reuters · 2d ago

Please log in to view news